Editor's Note: Occasionally, an opportunity comes to our attention that we believe readers like you will find valuable. The message below from one of our partners is one we believe you should take a close look at.

Dear Fellow Investor,

The challenge in treating Alzheimer's isn't the lack of drugs. It's that you can't get those drugs to reach the brain.

You see, the Blood-Brain-Barrier stops 100% of large-molecule drugs from getting to the brain. Small-molecule drugs only fare slightly better. 98% can't make it past the Blood-Brain-Barrier.

Nature does this in order to protect the brain. So the question is -

How do we ever cure Alzheimer's when our drugs can't even reach the brain?

On October 29, 2013, a Jeff Bezos-backed biotech had a radical idea: to employ a "drug smuggler" to help cross the blood-brain-barrier.

Big Pharma giants Biogen, Genentech and Sanofi were so stunned when it worked, they spent $1 billion for the rights to the treatment.

Never before has so much money invested in a single company so quickly.

Jim Cramer estimates this breakthrough would create the "Biggest Drug in the World."

We think this stock could rise 10,000% - if it's not taken over first.

There's just no way Big Pharma would let this company stay independent.

Pfizer, Novartis and Johnson & Johnson make billions selling Alzheimer's drugs each year. They have the most to lose. It's too much of a threat to their business.

That's why this tiny biotech is my #1 Biotech Stock for November.

"The Buck Stops Here,"

Trading involves risk. The information provided is NOT trading advice. Neither the Editors, the Publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from the newsletter. Past performance is no guarantee of future performance. This recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability for any purchase or order made from any company or entity mentioned or recommended in this email.

The information provided is for educational purposes only. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Actual results may differ. Nothing here constitutes a recommendation respecting the particular security illustrated.

This offer is brought to you by Web Impact LLC. Al Jerozolimskie 85, 02-001 Warsaw, Poland. If you would like to unsubscribe from receiving offers brought to you by Web Impact LLC click link below

This email was sent by: Ad Lucrum Newsletter
271 Nevil Road Bristol, Bristol, BS7 0XY, United Kindom
Update Profile
Unsubscribe
Manage Subscriptions